Résultats positifs de brivaracetam - NEUTRE - OC 69€
UCB annonce ce matin les résultats primaires de l’étude de phase III évaluant brivaracetam en tant que traitement d’appoint de l’épilepsie chez les patients atteints de crises partielles. UCB avait d’ores et déjà annoncé cet été que les résultats s’avéraient positifs, nous conduisant à appliquer une probabilité de succès de 75% (POS) pour le médicament. Nous maintenons à ce stade cette probabilité jusqu’à l’approbation de brivaracetam anticipé fin 2015. 100% de POS nous conduirait à apprécier notre objectif de cours de 1€ par action. Nous maintenons donc aujourd’hui notre objectif de 69€ (+5%) et notre opinion à NEUTRE.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.